FDA approves XIPERE for treatment of macular edema associated with uveitisOctober 25th 2021
Bausch + Lomb and Clearside Biomedical announced Monday that the U.S. Food and Drug Administration has approved XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular edema associated with uveitis.
Oyster Point Pharma reports FDA approval of TYRVAYA nasal spray for DED treatmentOctober 18th 2021
Oyster Point Pharma, Inc. announced Monday that the U.S. FDA has granted approval of its TYRVAYA (varenicline solution) nasal spray 0.03 mg for the treatment of dry eye disease (DED), making it the first — and only — nasal spray approved for DED treatment in the U.S
ROP: Treating and preventing blindness in preterm babiesOctober 18th 2021
Retinopathy of prematurity expert C. Armitage Harper, III, MD, of the Austin Retina Associates in Austin, Texas, discusses his experience in treating ROP cases across the globe, and his mission to prevent pre-term blindness in infants.
Analyzing real-world registry study of YUTIQ for chronic non-infectious posterior uveitisOctober 12th 2021
Ankur Shah, MD, discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.
Aerie reports positive phase 3 results for netarsudil 0.02% vs ripasudil 0.4% in lowering IOPOctober 12th 2021
Aerie Pharmaceuticals announced Tuesday positive topline results for the phase 3 trial evaluating netarsudil 0.02% versus ripasudil 0.4% for the treatment of open-angle glaucoma and elevated IOP.
Highlighting results from first FDA-reported study for treatment of presbyopiaSeptember 27th 2021
George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial (by Allergan, an Abbvie company) of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.
Evaluating efficacy, safety of intracameral dexamethasone 9% vs topical regimen for cataract surgerySeptember 26th 2021
Robert Weinstock, MD, discusses the efficacy and safety of intracameral dexamethasone suspension 9% compared to standard of care topical regimen for eyes receiving cataract surgery.
Study: Heru’s automated VF testing platform shows strong link to Humphrey Field AnalyzerSeptember 22nd 2021
A recent report by Heru Inc. has found that visual field (VF) results from re:Vive, its wearable testing platform, have a strong association to the ZEISS Humphrey Field Analyzer (HFA).